# Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

> **NCT04764942** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 39 (actual)

## Conditions studied

- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Selinexor
- **PROCEDURE:** X-Ray Imaging
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04764942
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-06
- **Primary completion:** 2026-05-06
- **Final completion:** 2027-12-17
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764942, "Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04764942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*